Hesperidin RCT in MS (NECTAR-MS)
A Randomized, Placebo-Controlled Trial of Hesperidin for Fatigue,Mood, and Cognitive Function in Multiple Sclerosis
This study is a randomised, double-blind, placebo-controlled trial investigating the effects of Hesperidin supplementation on cognitive function, fatigue, and stress.
Participants will be randomly assigned to receive either 500mg of Hesperidin or a matching placebo daily for 12 weeks. The primary outcome is fatigue, with secondary outcomes including cognitive performance and mood. The trial seeks to determine if this dietary intervention offers symptom-alleviating benefits.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Multiple Sclerosis (MS) is a chronic autoimmune condition characterized by neuro-inflammation, oxidative stress, and demyelination, often resulting in debilitating fatigue and cognitive dysfunction. While disease-modifying therapies exist, there is a significant need for accessible, low-risk adjunct interventions to manage these daily symptoms.
Hesperidin is a flavanone found primarily in citrus fruits (e.g., oranges, lemons). Preclinical research using Experimental Autoimmune Encephalomyelitis (EAE)-the standard animal model for MS-has demonstrated that hesperidin supplementation can reduce disease severity and incidence, likely due to its potent anti-inflammatory and antioxidant properties. However, there is a paucity of randomized controlled trials translating these findings to human MS populations.
Study Design & Methodology. This study is a remote, randomised, double-blind, placebo-controlled, parallel-group trial in adults with Multiple Sclerosis. Participants will be randomized to receive either 500mg/day of Hesperidin or a matching placebo for a duration of 12 weeks.
Statistical Analysis Plan. Data will be analysed using linear mixed-effects models. For the primary outcome (MFIS total score) and each secondary outcome, change from baseline to week 12 will be compared between intervention and placebo using fixed effects for group, time (baseline, week 12), and the group × time interaction, with a participant-level random intercept. The treatment effect will be estimated from the group × time interaction. Exploratory analyses will test whether baseline habitual diet modifies the intervention effect by adding a diet × group × time interaction term, with habitual diet operationalised using FFQ-derived polyphenol intake (energy-adjusted) and the Dietary Inflammatory Index (DII). In addition, exploratory symptom network analyses will examine whether the pattern of associations among symptoms differs between groups and changes from baseline to week 12.
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Hayley Young, PhD
- Phone Number: +44 (0) 1792 295908
- Email: h.a.young@swansea.ac.uk
Study Locations
-
-
Wales
-
Swansea, Wales, United Kingdom, SA2 8PP
- Recruiting
- FHMLS, Nutrition Lab
-
Contact:
- Hayley A Young, PHD
- Phone Number: +44 (0) 1792 295908
- Email: h.a.young@swansea.ac.uk
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Diagnosis of Multiple Sclerosis, Aged 18 years or older.
Exclusion Criteria:
- Known food allergies, intolerances, or significant gastrointestinal (GI) problems, Participants under the age of 18 years.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Hesperidin
Participants receiving Hesperidin capsules for 12 weeks.
|
500 mg/day Hesperidin capsules for 12 weeks
|
|
Placebo Comparator: Placebo Comparator
Participants receiving matching placebo capsules for 12 weeks.
|
Matching maltodextrin capsules for 12 weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fatigue
Time Frame: Baseline and Week 12
|
Fatigue will be assessed using the Modified Fatigue Impact Scale (MFIS; Fisk et al., 1994), with the MFIS total score as the primary endpoint.
MFIS subscale scores (physical, cognitive, psychosocial) and the Fatigue Severity Scale (FSS; Krupp et al., 1989) will be analysed as secondary outcomes to determine effects across different components of fatigue.
|
Baseline and Week 12
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mood and Stress
Time Frame: Baseline and Week 12
|
Mood and stress symptoms will be assessed using the Depression Anxiety Stress Scales (DASS).
Secondary outcomes will include the Depression, Anxiety, and Stress subscale scores.
|
Baseline and Week 12
|
|
Cognitive Function Battery
Time Frame: Baseline and Week 12
|
Global cognitive performance will be summarised using a composite score calculated as the mean of standardized (z) scores from a prespecified cognitive battery including: Continuous Performance Task (attention), Auditory Verbal Learning Task (verbal memory), Digit Symbol Substitution Task (speed of information processing), Stroop Task (selective attention/inhibitory control), and Trail Making Task (processing speed/set-shifting).
Scores will be coded so that higher values indicate better performance (completion time measures will be reverse-scored prior to standardisation).Individual task outcomes will also be analysed separately to explore domain-specific effects (attention, memory, speed).
Fatigue/mood ratings are taken before and after the test to assess cognitive fatigue relating to the tests.
|
Baseline and Week 12
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Hayley A Young, PHD, Swansea University
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Nervous System Diseases
- Autoimmune Diseases
- Immune System Diseases
- Demyelinating Autoimmune Diseases, CNS
- Autoimmune Diseases of the Nervous System
- Demyelinating Diseases
- Multiple Sclerosis
- Heterocyclic Compounds, 1-Ring
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Pyrans
- Carbohydrates
- Glycosides
- Benzopyrans
- Flavonoids
- Chromones
- Flavanones
- Hesperidin
Other Study ID Numbers
Other Study ID Numbers
- NECTAR-MS
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.